Back to shop
Reta (GLP-3)
Weight Loss

Reta (GLP-3)

Lyophilized *MUST BE RECONSTITUTED* Meet Reta (GLP-3) , a GGG tri-agonist that uniquely targets GLP-1 and GIP receptors while also activatin

$125
Select Vial Size

Lyophilized *MUST BE RECONSTITUTED* Meet Reta (GLP-3) , a GGG tri-agonist that uniquely targets GLP-1 and GIP receptors while also activating the glucagon receptor. Its actions on these receptors offer a comprehensive approach to research distinct from older GLP-1 agonists.

Important Research Notice

Research use only. Not for human consumption. This product is intended solely for laboratory research and educational applications. It is not designed for use in the diagnosis, treatment, cure, or prevention of any disease or medical condition. By purchasing this product, you acknowledge that this product is intended for research use only and agree to use it in accordance with all applicable laws and regulations.

References

  1. Reta (GLP-3) - Peptide Center guide
  2. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 TrialThe New England journal of medicine, 2023
  3. Retatrutide-A Game Changer in Obesity PharmacotherapyBiomolecules, 2025
  4. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trialsDiabetes, obesity & metabolism, 2026
  5. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USALancet (London, England), 2023
  6. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trialNature medicine, 2024
  7. The power of three: Retatrutide's role in modern obesity and diabetes therapyEuropean journal of pharmacology, 2024